Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Po-Hung Lin

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Annals of Surgical Oncology|June 8, 2023
Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?Kai-Jie Yu, Sy-Yuan Chen, Po-Hung Lin, et al.
Cancers|February 25, 2023
Replacement Instead of Discontinuation of Bacillus Calmette-Guérin Instillation in Non-Muscle-Invasive Bladder CancerPo-Ting Lin, Wei-Kang Hung, Ying-Hsu Chang, et al.
Journal of Robotic Surgery|July 10, 2025
Predicting hemorrhagic complications in robotic-assisted partial nephrectomy for renal tumors: simplifying risk assessment with tumor diameter and depthI-Hung Shao, Chung-Lin Lee, Yu-Hsiang Lin, et al.
BJU International|January 3, 2025
Selective treatment de-escalation in advanced prostate cancer: have we come full circle?Bryan Chong, Marniza Saad, Tsung Wen Chong, et al.
Oncology Letters|August 22, 2024
Periprostatic adipose tissue inhibits tumor progression by secreting apoptotic factors: A natural barrier induced by the immune response during the early stages of prostate cancerI-Hung Shao, Tzu-Hsuan Chang, Ying-Hsu Chang, et al.
Neoplasia (New York, N.Y.)|November 14, 2025
Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancerChiu-Lien Hung, Wen-Ning Hsu, Tsan-Chun Wang, et al.
International Journal of Cancer|November 8, 2022
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerHung-Kai Chen, Po-Jung Su, Yan-Lin Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 3, 2023
Impact of pathological response on oncological outcomes in patients with upper tract urothelial cancer receiving neo-adjuvant chemotherapyChih-Chin Yu, Chao-Hsiang Chang, Jen-Kai Fang, et al.
Frontiers in Oncology|June 20, 2022
The Value of Preoperative Local Symptoms in Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Retrospective, Multicenter Cohort StudyHsin-Chih Yeh, Chao-Hsiang Chang, Jen-Kai Fang, et al.
Scientific Reports|March 26, 2025
Preoperative ECOG performance status as a predictor of outcomes in upper tract urothelial cancer surgeryTsung-Mu Yang, I-Hsuan Alan Chen, Chia-Cheng Yu, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Annals of Surgical Oncology|June 8, 2023
Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?Kai-Jie Yu, Sy-Yuan Chen, Po-Hung Lin, et al.
Cancers|February 25, 2023
Replacement Instead of Discontinuation of Bacillus Calmette-Guérin Instillation in Non-Muscle-Invasive Bladder CancerPo-Ting Lin, Wei-Kang Hung, Ying-Hsu Chang, et al.
Journal of Robotic Surgery|July 10, 2025
Predicting hemorrhagic complications in robotic-assisted partial nephrectomy for renal tumors: simplifying risk assessment with tumor diameter and depthI-Hung Shao, Chung-Lin Lee, Yu-Hsiang Lin, et al.
BJU International|January 3, 2025
Selective treatment de-escalation in advanced prostate cancer: have we come full circle?Bryan Chong, Marniza Saad, Tsung Wen Chong, et al.
Oncology Letters|August 22, 2024
Periprostatic adipose tissue inhibits tumor progression by secreting apoptotic factors: A natural barrier induced by the immune response during the early stages of prostate cancerI-Hung Shao, Tzu-Hsuan Chang, Ying-Hsu Chang, et al.
Neoplasia (New York, N.Y.)|November 14, 2025
Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancerChiu-Lien Hung, Wen-Ning Hsu, Tsan-Chun Wang, et al.
International Journal of Cancer|November 8, 2022
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerHung-Kai Chen, Po-Jung Su, Yan-Lin Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 3, 2023
Impact of pathological response on oncological outcomes in patients with upper tract urothelial cancer receiving neo-adjuvant chemotherapyChih-Chin Yu, Chao-Hsiang Chang, Jen-Kai Fang, et al.
Frontiers in Oncology|June 20, 2022
The Value of Preoperative Local Symptoms in Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Retrospective, Multicenter Cohort StudyHsin-Chih Yeh, Chao-Hsiang Chang, Jen-Kai Fang, et al.
Scientific Reports|March 26, 2025
Preoperative ECOG performance status as a predictor of outcomes in upper tract urothelial cancer surgeryTsung-Mu Yang, I-Hsuan Alan Chen, Chia-Cheng Yu, et al.
Pageof 8